Nektar Therapeutics Dossier - Source-backed chat

Nektar Therapeutics

NKTRNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.09

Intrinsic Value $23.26median of 2 methodsbased on filings through 30 Jun 2026

Market Price $46.99Price as of 1 Oct 2026

Significantly overvaluedIntrinsic value is 50% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (-50%)

Data confidence Sign in to view data confidence

Market Cap $1.6B

Enterprise Value $1.8B

Shares Outstanding 31.7M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Nektar Therapeutics has successfully pivoted its focus from oncology to immunology, centered around its lead asset rezpegaldesleukin (REZPEG), a first-in-class regulatory T-cell (Treg) stimulator. Following two major public offerings in early 2026, the company has built a robust cash balance exceeding $1 billion, extending its operational runway into the third quarter of 2028. This financial strength fully funds the upcoming late-stage clinical trials, including the Phase 3 ZENITH-AD study in atopic dermatitis scheduled to launch by July 2026. However, near-term commercial revenue remains negligible following the sale of its Huntsville manufacturing facility in late 2024, leaving the company's valuation highly dependent on binary clinical trial readouts. Given that the first major Phase 3 data readout is not expected until mid-2028, the stock is likely to remain range-bound, justifying a Hold rating.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$80.00

Mean target$153.22

High · most bullish analyst$192.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$80.0015%

REZPEG encounters safety concerns or fails to show competitive efficacy in the Phase 3 atopic dermatitis trial, or the FDA mandates restrictive trial designs during the End-of-Phase 2 meeting for alopecia areata. High R&D cash burn rapidly depletes the cash reserves, forcing dilutive capital raises and severely depressing the stock's valuation.

Base CaseCentral scenario

$153.2260%

Matches the consensus mean

The Phase 3 ZENITH-AD trial in atopic dermatitis initiates on schedule in mid-2026, and the company successfully aligns with the FDA on the Phase 3 design for alopecia areata. Cash burn remains controlled within guided parameters, and the stock trades in line with its net cash value and risk-adjusted pipeline potential as clinical milestones progress.

Bull CaseUpside scenario

$192.0025%

REZPEG demonstrates superior, highly differentiated long-term durability and safety in the Phase 3 ZENITH-AD trial compared to existing biologics like Dupixent. This clinical success triggers a lucrative global co-development partnership with a major pharmaceutical firm, unlocking substantial upfront milestone payments and validating the platform's commercial potential.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong balance sheet with over $1 billion in cash and investments post-April 2026 financing, providing an operational runway into Q3 2028.
Differentiated mechanism of action for lead asset REZPEG, targeting regulatory T-cells to address underlying immune dysfunction.
Clear late-stage clinical path with the Phase 3 ZENITH-AD trial in atopic dermatitis initiating by July 2026.

Key Investment Risks

High binary clinical development risk, with valuation heavily dependent on the success of a single lead asset (REZPEG).
Intense competition in the atopic dermatitis and autoimmune markets from established blockbusters and emerging therapies.
Lack of near-term commercial product revenue, relying entirely on non-cash royalties and speculative clinical milestones.

Thesis Invalidation Triggers

Delay or failure to initiate the Phase 3 ZENITH-AD trial by July 2026.
Unfavorable regulatory feedback from the FDA during the End-of-Phase 2 meeting for alopecia areata.
Unexpected safety signals or adverse events emerging from the ongoing REZOLVE-AA or REZOLVE-AD observation periods.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.